Stock Market & Financial Investment News

XOMA finalizes plan for gevokizumab Phase 3 clinical program in PGXOMA announced that based on its meeting with the FDA, the company is finalizing its plans for a gevokizumab Phase 3 program in pyoderma gangrenosum, or PG, a rare neutrophilic dermatosis of painful expanding necrotic skin ulcers. During the meeting, the Company and the FDA reviewed the data generated from XOMA's pilot trial in six PG patients. The pilot study was designed to determine if gevokizumab, an IL-1 beta modulating antibody, should be explored in pivotal studies in patients with active PG. XOMA is incorporating the FDA's verbal and written responses regarding the clinical design of the studies into a final Phase 3 program, which it will submit to the Agency for any final comments. The Phase 3 program is expected to include two double-blind, placebo-controlled clinical studies, each of which is designed to enroll approximately 60 patients with active PG. The primary endpoint is complete wound closure of the target ulcer at approximately four months. XOMA anticipates conducting these parallel studies in the United States and several other countries.

XOMA CFO Fred Kurland to retire, Thomas Burns to succeedXOMA announced Thomas Burns, vice president, Finance, will succeed Fred Kurland as CFO when Kurland retires from his role as vice president, Finance, CFO and Secretary effective April 3. Burns joined the XOMA finance team in 2006.